Compare Marathon Petroleum Corp (MPC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Marathon Petroleum Corp trades at $401.83 (market cap $111.70B), while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Marathon Petroleum Corp is the larger of the two by market cap, and Marathon Petroleum Corp pays the higher dividend (1.01%). Which is the better fit depends on your goals.
| MPC | REGN | |
|---|---|---|
Market Cap | $111.70B | $83.43B |
Sector | Energy | Health |
52-Week High | $399.44 | $852.03 |
52-Week Low | $162.63 | $555.51 |
Enterprise Value | $138.23B | $78.14B |
Dividend Yield | 1.01% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $397.77, up 2.28% today, and is near its 52-week high. The stock shows strong momentum with bullish technical signals and has consistently beaten earnings estimates in recent quarters. Key fundamentals include a P/E of 13.79, robust ROE of 47.9%, and positive cash flow trends. Recent news highlights refinery efficiency gains and geopolitical tailwinds boosting energy sector sentiment.
Outlook remains positive given strong analyst consensus (78.79% buy ratings) and projected revenue growth to $153.6B in 2026. Risks include cyclical energy demand volatility and rising debt-to-asset ratios. The stock offers value through earnings momentum but faces headwinds from macroeconomic uncertainty.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
